Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2020 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo

Dose escalation completed as last patient enrolled into Part A of TRAVERS studyInterim results to be announced in Q3 of 2020 Hamilton, Bermuda, July 29, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
May 26, 2020 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study

Administration of intranasal betahistine 30 mg shows statistically significant reduction in olanzapine-induced weight gainTreatment well tolerated and safe with no adverse effectsEnrollment into Phase...
April 16, 2020 07:00 ET | Source: Auris Medical AG

Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results

Phase 1b trial with intranasal betahistine for prevention of antipsychotic-induced weight gain progressing towards final read-outPhase 2 trial with intranasal betahistine for treatment of acute...
April 03, 2020 17:00 ET | Source: Auris Medical AG

Auris Medical Provides Update on Intranasal Betahistine Development Program

Phase 1b trial with AM-201 proceeding as planned to data read-out in early May 2020Enrollment into Phase 2 trial with AM-125 impacted by COVID-19 pandemicCompany to report 2019 second-half and full...
March 05, 2020 08:30 ET | Source: Auris Medical AG

Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine

Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020Phase 2 trial with...
February 25, 2020 08:30 ET | Source: Auris Medical AG

Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model

Hamilton, Bermuda, February 25, 2020 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
January 10, 2020 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Notice of Allowance for European Patent Application

Received “Intention to Grant” notice from European Patent OfficeApplication covers invention of oral treatment for tinnitus Hamilton, Bermuda, January 10, 2020 – Auris Medical Holding Ltd. (NASDAQ:...
December 30, 2019 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss

Hamilton, Bermuda, Dec. 30, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
October 11, 2019 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain

Hamilton, Bermuda, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
September 13, 2019 09:00 ET | Source: Auris Medical AG

Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program

Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...